Sat, Feb 28, 2015, 9:37 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

MELA Sciences, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • teragr50 teragr50 Jul 13, 2011 12:06 PM Flag

    JP Morgan

    where to place it must be your decision.

    Crossfinder appeared on bid for 400,000 shares...why, why, why!!!?

    We may be very close to a catalyst.

    I seriously question why the FDA has been so ineffectual and unfair with this company, just as they had been with Dendreon for a very long time.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • >> I seriously question why the FDA has been so ineffectual and unfair with this company ...

      I don't think it is the FDA that is being unfair to Mela Sciences. IMO, it is one or few of the the "renegade" reviewers at the FDA that give Mela much grief. My belief is a (or perhaps several) main FDA reviewer had put himself in a tough position and is looking for a face-saving way out.

      • 2 Replies to oatbtc
      • <<My belief is a (or perhaps several) main FDA reviewer had put himself in a tough position and is looking for a face-saving way out.>>

        The guy has backed himself into a corner with I believe no legit reason to deny as much as he would like to have one. It's a shame that MELA, investors and potential patients are being jerked around by this guy.

      • Looking for a way out??? My God, buy the dumb bastar.. a new pair of glasses if he has that much trouble looking. Anyone who can't figure even a 'face saving' way out in this amount of time, isn't smart enough to hold that job.

        Speaking of that, according to another thread posted here tonight, changes in the medical products area of the FDA are coming. Maybe, just maybe...

 
MELA
1.77-0.07(-3.80%)Feb 27 3:58 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.